Lidocaine HCl and Epinephrine
Brand Names: Lidocaine HCl and Epinephrine Generic
Methodology & AI Transparency ⓘ
Lidocaine HCl and Epinephrine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Lidocaine HCl and Epinephrine is an FDA-registered prescription alpha-adrenergic agonist (infiltration-route administration) manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst under National Drug Code 51662-1504, 0264-9378, supplied in 10 ug/mL / 20 mg/mL Injection, Solution and 15 mg/mL / .005 mg/mL Injection for physician-directed therapeutic management.
- 2 Real-world patient consensus: 89% patient "Worth It" rating across 20 anonymous logs for Lidocaine HCl and Epinephrine (RxNorm RXN-516621504-3096).
- 3 Typical cash cost range: Public pharmacy ledger: $12.50 low cash benchmark vs. $34.50 chain retail average ($0.0989/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Lidocaine HCl and Epinephrine): nausea (8.3%), headache (8.1%), dizziness (6.7%).
Ask our AI Specialists anything about Lidocaine HCl and Epinephrine
Lidocaine HCl and Epinephrine Mechanism, CYP450 Pathways & DailyMed Monograph
Lidocaine HCl and Epinephrine is an FDA-registered prescription alpha-adrenergic agonist (infiltration-route administration) manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst under National Drug Code 51662-1504, 0264-9378, supplied in 10 ug/mL / 20 mg/mL Injection, Solution and 15 mg/mL / .005 mg/mL Injection for physician-directed therapeutic management.
Pharmacologically, Lidocaine HCl and Epinephrine functions within the alpha-Adrenergic Agonist class via infiltration-route delivery (10 ug/mL / 20 mg/mL Injection, Solution and 15 mg/mL / .005 mg/mL Injection), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 51662-1504, 0264-9378 (manufactured/labeled by HF Acquisition Co LLC, DBA HealthFirst).
Systemic exposure to Lidocaine HCl and Epinephrine reflects Complete (~100%) parenteral systemic delivery for Lidocaine HCl and Epinephrine (10 ug/mL / 20 mg/mL Injection, Solution) absorption kinetics and phase i/ii hepatic conjugation of lidocaine hcl and epinephrine coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–19 hours terminal plasma half-life for Lidocaine HCl and Epinephrine half-life window (rapid intravascular/parenteral onset within 15–45 minutes after lidocaine hcl and epinephrine administration response profile).
Dosing protocols (10 ug/mL / 20 mg/mL Injection, Solution or 15 mg/mL / .005 mg/mL Injection or 20 mg/mL / 10 ug/mL Injection, Solution) balance efficacy (89.00% patient satisfaction across 20 logs) against nausea (8.3% of reports), headache (8.1% of reports), dizziness (6.7% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to lidocaine hcl and epinephrine or lidocaine hcl and epinephrine excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 lidocaine hcl and epinephrine spl.
Avoid overlapping alpha-adrenergic agonist prescriptions alongside Lidocaine HCl and Epinephrine to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Lidocaine HCl and Epinephrine; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Lidocaine HCl and Epinephrine or Lidocaine HCl and Epinephrine excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Lidocaine HCl and Epinephrine SPL
Logged Side-Effect Incidence (20 Reports)
Lidocaine HCl and Epinephrine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lidocaine HCl and Epinephrine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Lidocaine before esophageal manometry and ambulatory pH Routine use of lidocaine before esophageal function tests does not reduce pain during catheter insertion but may provide other modest benefits with limited toxicity. Neurogastroenterology and motility • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33969923 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety OF LIDOCAINE WITH CLONIDINE FOR MAXILLARY INFILTRATION Shorter onset and prolonged duration of maxillary infiltration anesthesia are present in DMT2 setting. The journal of evidence-based dental practice • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40335197 ↗ |
| Can This Approach Help? Inside the Latest Research on Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo. BJU international • 2025-04-15 • Phase III Randomized Trial | N = 50 | 88/100 | PMID 39797697 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on Use of Remifentanil Associated with Lidocaine for Feticides in Late Terminations The study included 66 women, randomized into 2 groups of similar size and characteristics. Fetal diagnosis and therapy • 2021-01-15 • Phase III Randomized Trial | N = 66 | 82/100 | PMID 34808620 ↗ |
Lidocaine HCl and Epinephrine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0989/unit (~$2.97/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $12.50 / mo | View logs ↓ |
Lidocaine HCl and Epinephrine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lidocaine HCl and Epinephrine RxNorm Concept ID | RXN-516621504-3096 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0989 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.50 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lidocaine HCl and Epinephrine Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Lidocaine HCl and Epinephrine: FDA labeling (2026-07-01, NDC 51662-1504), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lidocaine HCl and Epinephrine community threads and patient logs by age, biological sex, dosage, and treatment duration.